AbbVie has become the latest large pharmaceutical company to dip its toes into psychedelic drug development as it announced what might be the most substantial foray of its kind this morning. The company, which is among the largest pharmaceutical firms in the world, announced a collaboration and option-to-license agreement with the privately held psychedelic drug developer Gilgamesh Pharmaceuticals.

Source

Previous articleThe Other Side of Veteran Healing: Secondary PTSD and Post-Retreat Family Dynamics
Next articleUnlocking Creativity: How Psychedelics Are Influencing Modern Design